Fig. 1: A scheme that illustrates major mechanisms of action by Her2-targeting agents.
From: Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
Antibody-based therapeutics pertuzamab and trastuzamab interact with the extracellular domain of Her2. Tyrosin kinasse inhibitors (lapatinib, neratinib, and pyrotinib) interact with the intracellular domain of Her2.
